|Bid||186.45 x 100|
|Ask||187.85 x 200|
|Day's Range||186.12 - 188.56|
|52 Week Range||133.64 - 191.10|
|PE Ratio (TTM)||16.98|
|Dividend & Yield||4.60 (2.45%)|
|1y Target Est||N/A|
Learn how this immigrant entrepreneur built a $5 billion company from scratch. This is her story.
Last month, Gilead Sciences (GILD) made big news when it announced the acquisition of Kite Pharma (KITE). For the most part, analysts were bullish on the deal, with the noted exception being Leerink's Geoffrey Porges and Bradley Canino. The pair penned a note late last month explaining why they were not excited by Gilead’s latest purchase.
In 2016, Roche Holding AG sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the U.S. Food and Drug Administration approved what’s expected to be a less-expensive version.